NCT06083922 2026-04-16
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Memorial Sloan Kettering Cancer Center
Pfizer
Pfizer
Memorial Sloan Kettering Cancer Center
Eastern Cooperative Oncology Group
Intergroupe Francophone du Myelome
Gilead Sciences
Celgene